FDA warns Ohio OTC drugmaker over lots released after failing microbial tests
FDA called the Streetsboro, Ohio, firm's August response inadequate and said its 2023 inspection found similar problems with validation and microbial investigations.
Key takeaways
- FDA issued a warning letter on November 10, 2026, to Natural Essentials, Inc., an over-the-counter drug manufacturer in Streetsboro, Ohio.
- The letter says the company released drug lots after microbial growth turned up in final release testing, without identifying the organisms or finding a root cause.
- FDA said the company released most of one lot that had a confirmed out-of-specification assay result, relying on additional limited sampling.
- FDA called the company's August 11, 2026, response inadequate and noted that its 2023 inspection had found incomplete system validation and inadequate microbial investigations.
- For crews: the public letter redacts product names and lot numbers, and it reports no recall, so the record cannot be matched to any specific product.
The U.S. Food and Drug Administration issued a warning letter on November 10, 2026, to Natural Essentials, Inc., a manufacturer of over-the-counter drugs in Streetsboro, Ohio. The letter cites violations of current good manufacturing practice (CGMP) that FDA found during an inspection in June 2026 [1].
The letter came from FDA's Center for Drug Evaluation and Research. It says investigators documented the problems at the company's plant at 10375 State Route 43 from June 22 to 26, 2026 [1]. Most of the letter concerns how the firm handled failing laboratory results, including microbial growth detected in final release testing of finished drug products. FDA says the affected lots were released anyway [1].
Because the plant's methods, facilities or controls do not conform to CGMP, FDA wrote, the company's drug products are adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act [1]. The agency reviewed the company's August 11, 2026, response to its Form FDA 483 and concluded: "Your response is inadequate." [1]
What the records show
The letter carries reference number 320-27-22 and MARCS-CMS number 738543, and it lists the facility's FDA Establishment Identifier as 1520307 [1]. The cited violation falls under 21 CFR 211.192, which covers thorough investigation of unexplained discrepancies and of batches that fail to meet specifications, including batches already distributed [1].
FDA gave three examples of out-of-specification (OOS) and out-of-limit (OOL) results that the company did not adequately investigate [1]:
- Assay failure, partial release. One drug product lot had an assay result above its specification limit, and a retest confirmed the OOS result. The company did not reject the whole lot. Instead it released most of the lot on the strength of passing results from additional limited sampling. FDA wrote that rejecting only part of a batch suggests "your firm does not have well-controlled manufacturing and release procedures." [1]
- Microbial growth at final release. Between 2025 and 2026, the company ran several investigations into microbial growth found during final release testing of drug products. According to the letter, "You did not identify the recovered microorganisms." None of the investigations firmly established a root cause. The lots were released based on passing retests, with the original failures invalidated "without scientific justification," FDA wrote [1].
- System samples over limits. Between 2024 and 2026, the company ran multiple OOS and OOL investigations into samples from a redacted system that exceeded limits, including microorganism limits. FDA said these investigations did not ask whether the system was validated well enough to consistently meet United States Pharmacopeia monograph specifications and appropriate microbial limits [1].
"Passing retest results alone cannot serve as the basis for invalidating OOS results," the agency wrote [1]. The public version of the letter redacts product names, test names, lot numbers, the specification limit and the number of units released. Each appears as (b)(4) [1].
The company's response and FDA's assessment
According to the letter, the company blamed the failed lot on an inadequate processing time at a redacted step. It said it had revised procedures and retrained staff. It also acknowledged that some failures had not been investigated, started a retrospective excursion assessment, and changed its OOS procedure. The new procedure requires documented scientific justification and quality unit approval before any OOS result can be invalidated [1].
FDA found several gaps in that response. The agency said the scope and criteria of the retrospective batch review were undefined and the sampling strategy was still scientifically unjustified. It also said the company had no risk assessment for the released units of the failed lot and no retrospective risk assessment of finished lots released after microbial results were improperly invalidated [1]. FDA added that the response did not identify root causes for the contamination failures or describe interim controls to protect product quality while corrective and preventive actions (CAPA) are underway [1].
Why it matters for clinicians
The plant makes over-the-counter drug products, which patients buy and use without a prescription or clinical oversight. FDA's central concern is microbial: lots went to market after failing microbial results were set aside, and the organisms behind those failures were never identified, according to the letter [1].
The letter also describes an assay result that exceeded its specification and was confirmed on retest, yet most of that lot was released [1]. Because product names are redacted, the public record cannot be used to connect these findings to a specific product a patient reports taking.
Context
This was not FDA's first look at these problems. The letter says the agency's 2023 inspection of the facility noted incomplete validation of the same redacted system and inadequate investigations into microbial recoveries in its samples [1].
FDA states that the letter does not list every violation at the facility. It warns that failure to correct the problems may lead to regulatory or legal action without further notice, including "seizure and injunction." [1]
What the records do not tell us
- The letter does not name the affected products, lots or microorganisms. These details are redacted or were never determined.
- It does not say how many lots or units reached the market. The count for the partially released lot is redacted.
- It reports no illnesses, injuries or adverse events linked to the products.
- It does not mention any recall, and the records available for this report show none.
- The text of the letter available for this report ends partway through, after the first cited violation. Any further findings and any response deadline are not covered here.
- The records contain no public comment from the company beyond its response to FDA as summarized in the letter.
Questions readers ask
Why did FDA send Natural Essentials a warning letter?
FDA's November 10, 2026, letter cites current good manufacturing practice violations found during a June 22 to 26, 2026, inspection of the company's Streetsboro, Ohio, plant. FDA said the firm did not adequately investigate failing assay and microbial test results and released affected drug lots anyway.
Which Natural Essentials products are affected by the FDA warning letter?
The public letter identifies the products only as over-the-counter drugs. Product names and lot numbers are redacted as (b)(4).
Has Natural Essentials recalled any products?
The warning letter does not mention a recall, and the records available for this report show none.
Did FDA find problems at Natural Essentials before?
Yes. According to the letter, FDA's 2023 inspection noted incomplete validation of one of the facility's systems and inadequate investigations into microbial recoveries in its samples.
Sources
- FDA warning letter to Natural Essentials, Inc., MARCS-CMS 738543, November 10, 2026 — fda.gov (2026-11-17). fda.gov/inspections-compliance-enforcement-and-criminal-investigations
This is news, not medical advice. EMS clinicians: follow your local protocols and medical direction.


